{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:53:55Z","timestamp":1761630835270,"version":"3.37.3"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"IRCCS Casa Sollievo della Sofferenza","award":["RC2017"],"award-info":[{"award-number":["RC2017"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0200568","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T16:53:29Z","timestamp":1533056009000},"page":"e0200568","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis\/cirrhosis"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2600-3555","authenticated-orcid":true,"given":"Alessandra","family":"Mangia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruggero","family":"Losappio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Cenderello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Potenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Mazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Terreni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Copetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Minerva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Piazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Bacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Sogari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1002\/hep.26905","article-title":"Is genotype 3 of the hepatitis C virus the new villain?","volume":"59","author":"N Gossens","year":"2014","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.27095","article-title":"HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US Veterans with HCV","volume":"60","author":"F Kawal","year":"2014","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"S Blach","year":"2017","journal-title":"The Lancet Gastroenterology and Hepatology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus genotype 3 and advanced liver disease","volume":"63","author":"V Leroy","year":"2016","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"G Foster","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/liv.13534","article-title":"Sofosbuvir\/velpatasvir in patients with hepatitis C virus genotypes 1\u20136 and compensated cirrhosis or advanced fibrosis","volume":"38","author":"T Asselah","year":"2018","journal-title":"Liver Int"},{"key":"ref7","first-page":"457","article-title":"Effectiveness of sofosbuvir, ledipasvir\/sofosbuvir, or paritaprevir\/ritonavir\/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis","volume":"151","author":"GN Ioannou","year":"2016","journal-title":"C in the Veterans Affairs National Health System Gastroenterology"},{"key":"ref8","first-page":"339","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"D Ge","year":"2009","journal-title":"Nature"},{"key":"ref9","first-page":"5","article-title":"IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-na\u00efve patients with chronic HCV genotype 1 infection: the international observational Gen-C study","volume":"18","author":"A Mangia","year":"2016","journal-title":"SpringerPlus"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcholic fatty liver disease","volume":"40","author":"S Romeo","year":"2008","journal-title":"Nat Genetics"},{"key":"ref11","first-page":"995","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"48","author":"C Sarrazin","year":"2016","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to Direct acting antiviral drugs in interferon-free regimens","volume":"151","author":"JM Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"ref13","unstructured":"Hepatitis C guidance: AASLD-ILDSA Recommendations for testing, managing and treating Hepatitis C; 2016. Avaialble from:http:\/\/www.hcvguidelines.org<\/ext-link> (cited 2017, mar 15)"},{"key":"ref14","first-page":"153","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"1","year":"2017","journal-title":"J Hepatol"},{"key":"ref15","unstructured":"Aghemo A, Bruno R, Ciancio A, Coco B, Petta S, Toniutto P, et al. Documento di indirizzo dell\u2019Associazione Italiana per lo Studio del Fegato per l\u2019uso razionale di antivirali diretti di seconda generazione nelle categorie di pazienti affetti da epatite C cronica ammesse alla rimborsabilit\u00e0 in Italia; (2014, reviewed in September 2015th). Retrieved from: http:\/\/www.webaisf.org\/media\/33882\/documento_hcv_22set.2015.pdf<\/ext-link>"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","article-title":"Classification of chronic viral hepatitis: a need for reassessment","volume":"13","author":"PJ Scheuer","year":"1991","journal-title":"J Hepatol"},{"issue":"43","key":"ref17","doi-asserted-by":"crossref","first-page":"37085","DOI":"10.1074\/jbc.M111.290114","article-title":"Expression and characterization of a PNPLA3 isoform (I148M) associated with nonalcoholic fatty liver disease","volume":"286","author":"Y Huang","year":"2011","journal-title":"Journal of Biological Chemistry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jhep.2016.12.002","article-title":"Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience","volume":"66","author":"A Mangia","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American Association for the study of liver diseases. Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"MG Ghany","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"ref20","first-page":"S189","article-title":"Prevalence of pre-treatment NS5A and NS5B NI resistance Associated substitutions in HCV-infected patients enrolled in clinical trials in Asia","volume":"11","author":"L Wei","year":"2017","journal-title":"Hepatol Int"},{"key":"ref21","article-title":"Natural NS3, NS5A and NS5B HCV resistance is common in real practice, differently associated to HCV genotypes and response to NS5A inhibitors","volume":"64","author":"V Cento","year":"2016","journal-title":"Hematology"},{"issue":"20","key":"ref22","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"E Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and Ribavirin in HCV genotype 2 and 3","volume":"370","author":"S Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/liv.13383","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme","volume":"37","author":"C Hezode","year":"2017","journal-title":"Liver International"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"MCM Cheung","year":"2016","journal-title":"J Hepatic"},{"key":"ref26","first-page":"2618","article-title":"Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis N Engl","volume":"373","author":"MP Curry","year":"2015","journal-title":"J Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jhep.2017.06.033","article-title":"Microelimination. A path to global elimination of hepatitis C","volume":"67","author":"J Lazarus","year":"2017","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"ref28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?","volume":"38","author":"T Asselah","year":"2018","journal-title":"Liver Int"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: A partially randomized phase 3 clinical trial","volume":"67","author":"D Wyles","year":"2018","journal-title":"Hepatology"},{"key":"ref30","first-page":"2134","article-title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection N Engl","volume":"376","author":"M Bourli\u00e8re","year":"2017","journal-title":"J Med"},{"issue":"1","key":"ref31","first-page":"113","article-title":"Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients with Chronic HCV Infection: 2 Phase 3","volume":"153","author":"IM Jacobson","year":"2017","journal-title":"Randomized Trials Gastroenterology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"S1100","DOI":"10.1016\/S0016-5085(17)33706-X","article-title":"RS738409 SNP of PNPLA3 Gene Predicts Clinical Recovery in Patients with Decompensated Hepatitis C Cirrhosis After Attaining Sustained Virological Response","volume":"5","author":"A Vittal","year":"2017","journal-title":"Gastroenterology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0200568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T15:12:12Z","timestamp":1540221132000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0200568"}},"subtitle":[],"editor":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0200568","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2018,7,31]]}}}